PRKCA and heart failure: Animal models for heart failure indicate that pharmacological inhibition of PKCα may have therapeutic potential, as agents that regulate PKCα appear to be safer, with milder side effects compared to cAMP elevating agents [8,12,28,29,30,31,32,33,34,35].